PressRelease - Rxlogix

EMA Go-Live on PV Signal and PV Reports, implementing an advance, automated and integrated Safety Surveillance solution

We are pleased to announce that the European Medicines Agency (EMA) has successfully gone live on PV Signal and PV Reports, our industry-leading platform specifically supporting signal detection, analytics, and signal validation. With a safety database encompassing more than 35 million safety reports, EMA now operates one of the largest and advanced safety surveillance platforms powered by RxLogix technology. This implementation represents a major milestone, for EMA’s adopting next-generation […]

RxLogix and FDA Achieve Unprecedented Milestone in Patient Safety Automation

[Aventura, FL] – [8/1/2025] – RxLogix Corporation, a global leader in PV and drug safety solutions, proudly announces a groundbreaking achievement in collaboration with the U.S. Food and Drug Administration (FDA). Together, the teams have reached a significant milestone by successfully implementing a first-of-its-kind capability: running thousands of safety alerts across an entire product dictionary—spanning […]

The FDA Selects RxLogix Corporation Products to Support Safety Surveillance

Princeton, New Jersey, November 19, 2018 – RxLogix Corporation, a global leading provider of Safety and Pharmacovigilance (PV) Software and Services, today announced the signing of an agreement with Booz Allen Hamilton to support the implementation of PV Signal and PV Reports at the US Food and Drug Administration (FDA). The FDA is responsible for protecting […]

The FDA Goes-Live on RxLogix Corporation Solutions to Support Safety Surveillance

Princeton, New Jersey, November 10, 2021 – RxLogix Corporation, a global leading provider of end-to-end Safety and Pharmacovigilance (PV) Software and Services, today announced the Go-Live of FAERS II at the United States Food and Drug Administration (FDA). FAERS II utilizes the RxLogix integrated PV signaling platform consisting of PV Signal, PV Reports, and PV Analytics. […]

RxLogix Corporation Announces Landmark Partnership with the European Medicines Agency (EMA) for a Cutting-Edge Safety Solution

Amsterdam, Netherlands, December 7th 2023 — RxLogix Corporation, a global leading provider of end-to-end Safety and Pharmacovigilance (PV) Software and Services, is delighted to announce a strategic software agreement with the European Medicines Agency (EMA) to begin the development of the new Signal and Safety Analytics (SSA) platform. The SSA platform, which will include RxLogix […]

Search results for:

EMA Go-Live on PV Signal and PV Reports, implementing an advance, automated and integrated Safety Surveillance solution

RxLogix and FDA Achieve Unprecedented Milestone in Patient Safety Automation

The FDA Selects RxLogix Corporation Products to Support Safety Surveillance

The FDA Goes-Live on RxLogix Corporation Solutions to Support Safety Surveillance

RxLogix Corporation Announces Landmark Partnership with the European Medicines Agency (EMA) for a Cutting-Edge Safety Solution

eNewsletter/ Brochures/ White Papers

Get in touch with us

Follow us

Connect with us